Prostate cancer, according to the World Health Organization, is the second most common cancer in men. It occurs in 1.1 million people (15% of new cancer cases) and causes 307,000 deaths. These values place a heavy burden of mortality and morbidity on society. Considering the drawbacks of the current procedure, we expect that the use of our under development urine test, PROSTATOR, will result in several concrete benefits: (1) Improved prostate cancer diagnostic process, which is a medical necessity; (2) Non-invasive procedure (from urine), so there is no risk of patient discomfort, anxiety, infection and pain before diagnosis is made; (3) Urine can be easily collected on the first visit to a urologist, after the digital rectal exam, and sent to a laboratory; (4) improves the robustness of the diagnosis of prostate cancer by detecting all grades of prostate tumors; (5) Rapid results so that, if necessary, the patient can benefit from early treatment; (6) It is profitable with reduced costs and increased precision, when compared to the current commercial prostate tests. (7) Reduce diagnostic costs by avoiding unnecessary biopsies (45% of patients).
The PROSTATOR test highlights the presence of novel unreferenced biomarkers for prostate cancer within the urines of patients. In partnership with Curie Institute (Paris) several agreements have been obtained with multi centers to validate these novel markers and we are now in the process to spin out this discovery to make the test accessible for a large public.
